Mercaptopurine (MP) is the mainstay of curative therapy for acute lymphoblastic leukemia (ALL). We performed a genome-wide association study (GWAS) to comprehensively identify the genetic basis of MP intolerance in children with ALL in AALL03N1. MP dose intensity was defined as prescribed dose divided by the planned protocol dose during maintenance therapy.  Germline variants in <a href="https://www.ncbi.nlm.nih.gov/gene/55270">NUDT15</a> and <a href="https://www.ncbi.nlm.nih.gov/gene/7172">TPMT</a> were found to be strongly associated with MP intolerance in childhood ALL, which may have implications for treatment individualization in this disease.

Pharmacogenomics of Mercaptopurine Intolerance in Children with Acute    Lymphoblastic Leukemia (AALL03N1)

Mercaptopurine study with SNP Genotypes (Array) data on dbGaP (657 participants)

Pharmacogenomics of Mercaptopurine Intolerance in Children with Acute Lymphoblastic Leukemia (AALL03N1)

Description

Applying For Access

Summary